Skip to main content

The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.

Publication ,  Journal Article
George, DJ; Halabi, S; Shepard, TF; Sanford, B; Vogelzang, NJ; Small, EJ; Kantoff, PW
Published in: Clin Cancer Res
March 1, 2005

UNLABELLED: Interleukin-6 signaling can activate androgen receptor in a ligand-independent manner and may play an important functional role in hormone-refractory prostate cancer (HRCaP) progression and patient survival. Plasma and serum IL-6 levels have been associated with prostate cancer progression in several small studies. In order to evaluate its prognostic significance in metastatic HRCaP patients, we measured IL-6 in plasma collected at baseline from patients in a large cooperative group study [Cancer and Leukemia Group B 9480 (CALGB 9480)]. METHODS: 191 patients entered on CALGB 9480 had pretreatment plasma collected and centrally stored. Using a human IL-6 immunoassay, quantitative levels of IL-6 were measured in duplicate on 300 muL samples. The proportional hazard model was used to assess the prognostic significance of IL-6 in predicting overall survival. RESULTS: Median IL-6 level for the cohort of 191 patients was 4.80 pg/mL. Survival time among patients with IL-6 levels less than or equal to the median was 19 months (95% CI, 17-22) compared with 11 (95% CI, 8-14) months for patients above the median (P = 0.0004). In multivariate analysis, adjusting on performance status, lactate dehydrogenase, and prostate-specific antigen level, the hazard ratio was 1.38 (95% CI, 1.01-1.89; P = 0.043) using the median level as a cut point. Furthermore, a cut point of 13.31 pg/mL revealed robust prognostic significance with a hazard ratio of 2.02 (95% CI, 1.36-2.98; P = 0.0005). CONCLUSIONS: Plasma IL-6 level has prognostic significance in patients with metastatic HRCaP from CALGB 9480. These findings support using IL-6 levels in prognostic models and support the rationale for IL-6-targeted therapy in patients with HRCaP.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

March 1, 2005

Volume

11

Issue

5

Start / End Page

1815 / 1820

Location

United States

Related Subject Headings

  • Survival Analysis
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Multivariate Analysis
  • Middle Aged
  • Male
  • Interleukin-6
 

Citation

APA
Chicago
ICMJE
MLA
NLM
George, D. J., Halabi, S., Shepard, T. F., Sanford, B., Vogelzang, N. J., Small, E. J., & Kantoff, P. W. (2005). The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res, 11(5), 1815–1820. https://doi.org/10.1158/1078-0432.CCR-04-1560
George, Daniel J., Susan Halabi, Timothy F. Shepard, Ben Sanford, Nicholas J. Vogelzang, Eric J. Small, and Philip W. Kantoff. “The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.Clin Cancer Res 11, no. 5 (March 1, 2005): 1815–20. https://doi.org/10.1158/1078-0432.CCR-04-1560.
George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, et al. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 1;11(5):1815–20.
George, Daniel J., et al. “The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480.Clin Cancer Res, vol. 11, no. 5, Mar. 2005, pp. 1815–20. Pubmed, doi:10.1158/1078-0432.CCR-04-1560.
George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 1;11(5):1815–1820.

Published In

Clin Cancer Res

DOI

ISSN

1078-0432

Publication Date

March 1, 2005

Volume

11

Issue

5

Start / End Page

1815 / 1820

Location

United States

Related Subject Headings

  • Survival Analysis
  • Prostatic Neoplasms
  • Prostate-Specific Antigen
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Metastasis
  • Multivariate Analysis
  • Middle Aged
  • Male
  • Interleukin-6